The consumer healthcare industry is changing. Companies are separating from their pharmaceutical parents and brands are shifting from therapeutic solutions to preventative health and wellness options. These shifts bring a number of challenges for OTC firms, notes AdverCheck managing director James Walmsley in the second part of his chat with HBW. F…

Audio roundup of selected biopharma industry content from Scrip over the business week ended 28 February 2025. In this episode: which big companies face the least LOE hit?; IPOs rise in 2024; Pfizer cuts last AAV gene therapy program; balance and focus suggested for globalizing Chinese firms; and Scrip Asks on therapeutic area advances. https://ins…

Pink Sheet Executive Editor Derrick Gingery, Senior Writer Sarah Karlin-Smith and Editor-in-Chief Nielsen Hobbs, as well as Medtech Insight Managing Editor Elizabeth Orr, discuss the US Food and Drug Administration’s decision to call back many workers that were laid off and the next steps for the Trump Administration’s effort to reduce the size of …

Audio roundup of selected biopharma industry content from Scrip over the business week ended 21 February 2025. In this episode: 2025’S biggest launches; 2024 deal metrics declined; GSK’s meningococcal vaccine; Arcus’s kidney cancer results; and Novartis on its India hub. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quic…

UK law prohibits the advertising of prescription-only medicines. Nevertheless, some online pharmacies are marketing Rx drugs from “skinny jabs” to high strength eczema treatments, essentially selling prescription medicines directly to consumers, explains AdverCheck managing director James Walmsley. While regulators are cracking down on illegal prac…

Pink Sheet Executive Editor Derrick Gingery, Senior Writer Sarah Karlin-Smith, Senior Editor Sue Sutter, and Editor-in-Chief Nielsen Hobbs, as well as Medtech Insight Managing Editor Elizabeth Orr and HBW Insight Managing Editor Malcolm Spicer, discuss the most up-to-date information on the layoffs at the US Food and Drug Administration that were i…

Audio roundup of selected biopharma industry content from Scrip over the business week ended 14 February 2025. In this episode: delayed take-off for M&A?; Bain to acquire Mitsubishi Tanabe; clinical trials to look out for; how to work with Trump; and mid-cap biopharma winners and losers. https://insights.citeline.com/scrip/podcasts/scrips-five-must…

Pink Sheet Executive Editor Derrick Gingery, Editor-in-Chief Nielsen Hobbs, and special guest Michael McCaughan of Prevision Policy look at new Health and Human Services Secretary Robert F. Kennedy Jr.’s first assignment, a presidential commission on reducing chronic disease (:29), as well as former US Food and Drug Administration Commissioner Scot…

Citeline’s expert panel of reporters and analysts unpack the biggest deals, trends, and innovations from the JP Morgan Healthcare Conference. Discover what these developments mean for you and the future of the industry in 2025 and beyond.بقلم Citeline

트럼프 미 대통령의 재당선과 지정학적 불안요소가 제약바이오 시장과 기업에 어떤 영향을 미칠까? Scrip의 전문가 설문조사 기사를 요약한 내용입니다. https://insights.citeline.com/scrip/scrip-asks/scrip-asks-what-does-2025-hold-for-biopharma-part-3-impacts-of-political-change-in-us-and-beyond-CKTDR3BC2JBU5O6MUHDAKXGXHU/Playlist: soundcloud.com/citelinesounds/sets/korean-language-biopharma-mini…

Creativity can sometimes be about discovering what in retrospect seems obvious, like shoes that are shaped to fit our feet, marketing expert Beverley Law tells HBW Insight in the first episode of this season’s Over the Counter podcast. But this often requires stepping out of established approaches and patterns of thinking, she points out, which ten…

Audio roundup of selected biopharma industry content from Scrip over the business week ended 7 February 2025. In this episode: Novo outlines CagriSema strategy; Pfizer is back in the deal game; Vertex’s pain drug faces opportunities and headwinds; uncertain times for Korean pharma; and a view on women’s health at JPM.https://insights.citeline.com/s…

Introduction: Pink Sheet Executive Editor Derrick Gingery, Senior Writer Sarah Karlin-Smith, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs discuss the many commitments Robert F. Kennedy Jr. gave Sen. Bill Cassidy, R-LA, to secure his vote to move his Health and Human Services Secretary nomination to the Senate floor (:25). They also co…

Harness Therapeutics' CEO talked to In Vivo about the company's scientific strategy, and its plans for expansion and partnering in the neurodegeneration space.بقلم Citeline

Audio roundup of selected biopharma industry content from Scrip over the business week ended 31 January 2025. In this episode: biopharma VC fundraising recovers; Daiichi Sankyo’s big year ahead; Akero’s promising MASH results; ADCs attract new investments in China; and Scrip Asks on AI and data science. https://insights.citeline.com/scrip/podcasts/…

Summer Colling and Emma Wille speak with epidemiologists Ridwaan Ibrahim and Lucia Rodriguez-Garcia about the recent ISPOR conference. Ridwaan and Lucia discuss where they see new technologies like AI fitting into the epidemiology space as well as the advantages and disadvantages of using AI to analyze large volumes of real world data.…

Pink Sheet Executive Editor Derrick Gingery, Senior Writer Sarah Karlin-Smith, Senior Editor Sue Sutter, and Editor-in-Chief Nielsen Hobbs discuss the effect of Acting US Food and Drug Administration Commissioner Sara Brenner’s use of MAHA in her introductory memo (:35), the issues that emerged during MAHA founder and Health and Human Services Secr…

Audio roundup of selected biopharma industry content from Scrip over the business week ended 24 January 2025. In this episode: semaglutide in 2027 Medicare price negotiations; J&J expects revenue growth despite challenges; Roche’s China Accelerator makes progress; Scrip Asks about the impact of political change; and Datroway’s US approval in breast…

Pink Sheet reporter and editors try to answer some emerging questions about the US Food and Drug Administration now that President Donald Trump has taken office. They discuss the FDA’s acting leadership (:43), an ongoing communications freeze (7:45), along with the hiring freeze and travel ban (20:49). They also discuss the impact of several execut…

In Vivo speaks with Ashley Zender, CEO of Fauna Bio, a company using AI to identify drug targets based on natural disease resistance in animals. The company's $494m partnership with Eli Lilly is a testament to the value of their approach.بقلم Citeline

Audio roundup of selected biopharma industry content from Scrip over the business week ended 17 January 2025. In this episode: a look at JPM; J&J’s Intra-Cellular buy; how JPM Day 1 deals fit into BD strategy; Scrip asks about the global state of biopharma; and what will fuel M&A activity in India this year. https://insights.citeline.com/scrip/podc…

Pink Sheet editors consider ex-FDA officials’ advice for the Trump Administration on implementing FDA reforms (:24), comments CDER Director Patrizia Cavazzoni made before her departure from the agency about wanting to release review documents for applications that received complete response letters (12:35), and diverging trends between CDER and CBE…

Juho Jalkanen, CEO of Faron Pharma, discusses the importance of addressing unmet medical needs in cancer through breaking treatment resistance and developing long-term solutions. In Vivo questions the current progress of their lead asset BEXMAB and its potential moving forward.بقلم Citeline

Audio roundup of selected biopharma industry content from Scrip over the business week ended 10 January 2025. In this episode: key themes for JPM; 2024 launches a breakout for liver disease; obesity drug readouts this year; IgA nephropathy snapshot; and only half of 2024 launches were from big pharma.https://insights.citeline.com/scrip/podcasts/scr…

Pink Sheet editors discuss Center for Drug Evaluation and Research Director Patrizia Cavazzoni’s surprising retirement announcement (:32), the importance of the large bolus of guidance documents that the FDA released 6 January (12:42), and the FDA’s decision to continue reviewing and granting rare pediatric disease designations even though the prog…

트럼프 대통령의 취임 직전 열리는 2025년 JP모건 헬스케어 컨퍼런스에서 라이센스딜 및 M&A 뿐 아니라 미국 정치와 정책도 주목 받을 것이라는 Scrip 기사의 요약입니다.https://insights.citeline.com/scrip/conferences/jp-morgan/jpm-2025-deals-politics-and-parties-to-welcome-a-new-year-for-pharma-5XBXOFPQMNB3ZBWVSWIIY5Y7IM/Playlist: soundcloud.com/citelinesounds/sets/korean-language-biopharma-mini…

As we enter 2025, In Vivo convened a group of biotech executives for a wide-ranging conversation about dealmaking this year and the challenges and opportunities for companies in the cardiometabolic, longevity, radiopharmaceuticals and cancer spaces. Essential listening before JPM.بقلم Citeline

In this week’s Digital Health Roundup, Medtech Insight’s Marion Webb brings highlights from Deloitte’s 2025 Life Sciences Outlook Report with medtech leaders’ forecasting significant investments in AI/GenAI. Brian Bossetta talks about the US FDA’s newly formed Digital Health Advisory Committee. Elizabeth Orr highlights the pros and cons of penetrat…

In this episode of the In Vivo podcast, Harvard immunologist and co-founder of early-stage biotech Corner Therapeutics, Jonathan Kagan, talks about harnessing the power of the innate immune system by weaponizing dendritic cells and creating immunotherapies that are safer and more durable.بقلم Citeline

Emma and Summer meet with Datamonitor Healthcare analyst Ken Hoang, to discuss the non-alcoholic steatohepatitis (NASH) treatment marketبقلم Citeline

Scrip이 선정한 2024년의 Top 5 글로벌 제약바이오 뉴스입니다.https://insights.citeline.com/scrip/business/deals/the-top-five-pharma-stories-of-2024-GSROXP3WAZBWXGV4YP6VJML3YY/Playlist: soundcloud.com/citelinesounds/sets/korean-language-biopharma-miniبقلم Citeline

Audio roundup of selected biopharma industry content from Scrip over the business week ended 20 December 2024. In this episode: Pfizer’s 2025 policy outlook; made in China blockbuster elusive; Vertex’s pain plans; Q3’s top 10 drugs; and sickle cell disease at ASH. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-liste…

The Future Of eClinical Technology by Citelineبقلم Citeline

Generics Bulletin's editorial team discusses key topics from the year, including the latest rankings of the GB Top 50, Amgen's surprise launch of a US Eylea biosimilar, the EU's Urban Waste Water Treatment Directive and supply-chain issues for the off-patent sector.بقلم Citeline

Audio roundup of selected biopharma industry content from Scrip over the business week ended 13 December 2024. In this episode: a snapshot of the atopic dermatitis market; Bill Burns profile; GSK’s Blenrep makes a comeback; CML results at ASH; and what’s driving optimism on India. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-t…

Learn how utilizing a site network can improve clinical trial efficiency and scalability, data quality, patient access and recruitment, resource optimization, and regulatory compliance. Discover more about speeding clinical trials with the use of site networks.بقلم Citeline

Summer Colling speaks with Emma Wille about the Psychedelic Symposium at the University of Wisconsin-Madison and what the future of psychedelic therapeutics could look like.بقلم Citeline

Audio roundup of selected biopharma industry content from Scrip over the business week ended 6 December 2024. In this episode: Zepbound bests Wegovy; Novartis and PTC’s Huntingdon’s deal; Vabysmo hopes to ride new listing, data in Asia; Leo Pharma gains momentum; and Immunic’s hopes for MS drug. https://insights.citeline.com/scrip/podcasts/scrips-f…

In this episode of the In Vivo podcast, Peter Flynn, CEO of Arialys Therapeutics, discusses the exciting field of autoimmune neuropsychiatry and the company’s monoclonal antibody, which it is investigating for the treatment of a rare condition called anti-NMDA receptor encephalitis and potentially other indications.…

Pink Sheet reporter and editors discuss potential threats to the COVID-19 vaccine pediatric indications under the Trump Administration (:24), the DOGE commission’s search for spending cuts and its impact on the FDA (12:52), as well as a new 340B rebate pricing model that some pharma companies are implementing to contain the program’s costs (22:52).…

Emma and Summer meet with oncology analysts Neha Anand and David Dahan, to discuss an emerging class of drugs: bispecific antibodies.بقلم Citeline

In this episode of the In Vivo podcast, Michelle Werner, CEO of Alltrna, discusses using tRNA as a therapeutic modality for rare diseases, including those stemming from nonsense mutations.بقلم Citeline

Biopharma is evolving through collaboration, early-phase deal-making and innovation in precision medicine and AI. At BIO-Europe, Norstella's subject matter experts explored key trends shaping the industry, from market access strategies to sustaining growth through partnerships.In this episode, Izabela Chmielewska, Kevin Grogan, and Natasha Choukkar…

Audio roundup of selected biopharma industry content from Scrip over the business week ended 29 November 2024. In this episode: Marks on Trump’s threat to FDA; Amgen’s Phase II MariTide data lack clarity; Roche’s Poseida buyout; Roche’s CMO on his biotech lessons; and what Trump 2.0 might mean for India. https://insights.citeline.com/scrip/podcasts…

A preview of the 2024 Scrip Awards and an interview with last year’s Executive of the Year, David Zaccardelli, CEO of Verona Pharma.بقلم Citeline

Audio roundup of selected biopharma industry content from Scrip over the business week ended 22 November 2024. In this episode: Novo’s semaglutide looks good in NASH; J&J’s psoriasis drug hits multiple Phase III goals; NASH competition gets serious; China dominates APAC and increasingly global trials; and why has M&A decreased in 2024.https://insig…

Pink Sheet reporter and editors discuss concerns that the incoming administration could try to influence the upcoming FDA user fee reauthorization (:30), as well as the changes Dr. Mehmet Oz, President-elect Donald Trump’s controversial selection of to run the US Centers for Medicare and Medicaid Services, could impose if confirmed (22:35).#pharma …

Audio roundup of selected biopharma industry content from Scrip over the business week ended 15 November 2024. In this episode: muscling into the obesity market; AbbVie’s schizophrenia failure; Bayer will not take risky bets; generally strong Q2 for Japanese majors; and AstraZeneca juggles China and growth questions. https://insights.citeline.com/s…

Pink Sheet reporter and editors, and guest Michael McCaughan of Prevision Policy, continue the discussion of Donald Trump’s potential impact on the FDA, including how Robert F. Kennedy Jr. could change the agency as head of HHS (:37), whether lasting changes are coming to the FDA (13:00), and Commissioner Robert Califf’s request that industry help …

Scrip senior writer Joseph Haas discusses recent merger-and-acquisition activity in the biopharma sector with Gerardo Ubaghs, CFO of Frontier Medicines, and Jason Silvers, CFO of Generate Biomedicines. The panel looks at why M&A activity metrics declined during both the second and third quarters despite a strong start to the year and apparent posit…